{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Babal jha"}, {"accession": "MS:1000589", "name": "contact email", "value": "jhab@ccf.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Cleveland Clinic Lerner College of Medicine"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Babal K Jha"}, {"accession": "MS:1000589", "name": "contact email", "value": "jhab@ccf.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Taussig Cancer Institute of Cleveland Clinic Foundation"}]}], "datasetFiles": [{"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1014-(1).msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1014.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1015-(1).msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1015.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1017-(1).msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1017.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1018-(1).msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/19oct1018.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun401.msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun401.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun402.msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun402.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun701.msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun701.raw"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun702.mgf"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun702.msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550/Lum_20jun702.raw"}], "description": "Loss-of-function TET2 mutations (TET2MT) are common in myeloid neoplasia. TET2, a DNA dioxygenase, requires 2-oxoglutarate and Fe(II) to oxidize 5-methylcytosine. TET2MT thus result in hypermethylation and transcriptional repression. Ascorbic acid (AA) increases dioxygenase activity by facilitating Fe(III)/Fe(II) redox reaction and may alleviate some biological consequences of TET2MT by restoring dioxygenase activity. Here, we report the utility of AA in the prevention of TET2MT MN, clarify the mechanistic underpinning of the TET2-AA interactions, and demonstrate that the ability of AA to restore TET2 activity in cells depends on N- and C-terminal lysine acetylation and nature of TET2MT. Consequently, pharmacologic modulation of acetyltransferases and histone deacetylases may regulate TET dioxygenase-dependent AA effects. Thus, our study highlights the contribution of factors that may enhance or attenuate AA effects on TET2 and provides a rationale for novel therapeutic approaches including combinations of AA with class I/II HDAC inhibitor or sirtuin activators in TET2MT leukemia.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/09/PXD020550"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD020550"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD020550"}], "instruments": [{"accession": "MS:1001910", "name": "LTQ Orbitrap Elite"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "TET2, Ascorbic Acid, HAT, Sirtuins, HDAC, Lysine acetylation, Therapy, Prevention, MDS, Leukemia"}], "modifications": [{"accession": "MOD:00394", "name": "acetylated residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "32895473"}, {"accession": "MS:1002866", "name": "Reference", "value": "Guan Y, Greenberg EF, Hasipek M, Chen S, Liu X, Kerr CM, Gackowski D, Zarakowska E, Radivoyevitch T, Gu X, Willard B, Visconte V, Makishima H, Nazha A, Mukherji M, Sekeres MA, Saunthararajah Y, Oli\u0144ski R, Xu M, Maciejewski JP, Jha BK. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Commun Biol. 2020 3(1):493"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Context Dependent Effects of Ascorbic Acid Treatment in TET2 Mutant Myeloid Neoplasia"}